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Abstract
FINDbase (http://www.findbase.org) is a comprehensive data resource recording the
prevalence of clinically relevant genomic variants in various populations worldwide,
such as pathogenic variants underlying genetic disorders as well as pharmacoge-
nomic biomarkers that can guide drug treatment. Here, we report significant new
developments and technological advancements in the database architecture, leading
to a completely revamped database structure, querying interface, accompanied with
substantial extensions of data content and curation. In particular, the FINDbase
upgrade further improves the user experience by introducing responsive features
that support a wide variety of mobile and stationary devices, while enhancing
computational runtime due to the use of a modern Javascript framework such as
ReactJS. Data collection is significantly enriched, with the data records being divided
in a Public and Private version, the latter being accessed on the basis of data
contribution, according to the microattribution approach, while the front end was
redesigned to support the new functionalities and querying tools. The above-
mentioned updates further enhance the impact of FINDbase, improve the overall
user experience, facilitate further data sharing by microattribution, and strengthen
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the role of FINDbase as a key resource for personalized medicine applications and
personalized public health.
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1 | INTRODUCTION
In the postgenomic era, which is characterized by the exponential gen-
eration of DNA sequencing data, the need to comprehensively docu-
ment and deposit these data into well‐maintained and curated resources
is more important than ever. There have been numerous databases
developed to fulfill this need but only a fraction of those are widely
recognized and utilized. Such acceptance depends on data accuracy and
curation, which are crucial elements that distinguish a database that is
truly useful and acknowledged by the scientific community from others
that have been built by researchers at the side of their projects and tend
to be abandoned, mostly due to the lack of funding and interest deflation
(Patrinos & Brookes, 2005). Genomic databases with clinical relevance
can be categorized into three types: (a) general (or core) genomic
databases include genomic data with basic phenotypic description. Two
of the most well‐known are expert‐curated general genomic databases
with clinical relevance are ClinVar (https://www.ncbi.nlm.nih.gov/clinvar;
Landrum et al., 2016) and the Human Gene Mutation Database (HGMD;
http://www.hgmd.compareac.uk; Stenson et al., 2014); (b) locus‐specific
databases (LSDBs), which include genotypic information accompanied
with comprehensive and in‐depth phenotypic description of all deposited
variants, the majority of which are often contributed by researchers
directly to database curators and consists of unpublished information.
The HbVar database of human hemoglobin variants and thalassemia
mutations (http://globin.bx.psu.edu/hbvar; Giardine et al., 2014) is
among the most well‐respected LSDBs, while the Leiden Open Variation
Database (http://www.lovd.nl; Mitropoulou, Webb, Mitropoulos,
Brookes, & Patrinos, 2010) is a collection of LSDBs which tries to rectify
the extant content heterogeneity of the existing LSDBs (Fokkema
et al., 2011) and, most importantly, to address technical issues that
prevent the scientific community from developing and curating LSDBs,
by providing an easy‐to‐use web interface (c) the national/ethnic
genomic databases (NEGDBs), which comprehensively document the
prevalence of clinically relevant alleles in different populations and
ethnic groups worldwide (Patrinos, 2006).
The NEGDBs comprise a well‐defined group of genomic data-
bases that first appeared in the early 2000 (Patrinos, 2006) and are
used for population genetic studies, for example, to study gene/mu-
tation flow and admixture patterns, human demographic history, as
well as in genomic medicine and public health to facilitate patient
stratification and/or rationalization of drug use (Patrinos, 2006). These
databases can serve as a valuable complement to the data content of
the core databases and the LSDBs, in which this information is often
lacking or is poorly documented (Giardine et al., 2014).
In 2006, the Frequency of INherited Disorders (FINDbase; http://
www.findbase.org) database was established, aiming to fill the gap of a
worldwide database that would comprehensively document the pre-
valence of clinically relevant genomic variation allele frequencies in
various populations and ethnic groups worldwide (van Baal
et al., 2007). From its establishment, FINDbase contains only ag-
gregated data, that is, allele frequencies deprived from any personal
information of their carriers, to ensure data anonymity. In its begin-
nings, FINDbase accommodated data pertaining to the prevalence of
pathogenic genomic variants, leading for example, to monogenic dis-
orders; however, as of 2010, FINDbase's data content was expanded
to also include allelic frequency data for pharmacogenomic (PGx)
biomarkers in distinct data modules (Georgitsi et al., 2011b). FINDbase
has the most extensive content among all current NEGDBs and con-
stitutes one of the key resources for population‐specific clinically re-
levant genomic variation allele frequency data information deducted
from the number and origin of visitors, while it also complies with the
recommendations for genomic data collection from populations
(Patrinos et al., 2011). To keep FINDbase up‐to‐date and user‐friendly,
its user interface and querying module have undergone major
refurbishments and updates in 2010 (Georgitsi et al., 2011b), while its
data content is being continuously enriched and updated, where
needed, in response to user feedback (Papadopoulos et al., 2014;
Viennas et al., 2017). Still, the continuous data updates and influx
dictated further upgrade of the user interface so that data output is
expedited and provided in a timely manner.
Here, we present the next generation of the FINDbase world-
wide database, including significant technological advances in the
user interface, data output, and visualization, as well as data content
updates in both data modules, which substantially expands the ex-
isting functionalities and database content.
2 | METHODS
2.1 | Functionality and main user interface
components
In this update, the FINDbase user interface has been redesigned from
scratch, using a single‐page application that was built with the use of the
ReactJS framework. The interface was implemented as a responsive
application to optimize the user experience and facilitate easy navigation
of the user to retrieve genomic variant allele frequencies of pathogenic
variants or PGx biomarkers.
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The website consists of two standard components, namely the menu
and the footer, as well as one variable component that depends on user
navigation. The menu consists of different links, such as Home, Doc-
umentation, Map, Diseases, Genes, Frequency, and Researchers (Figure 1a),
and by clicking on them, the user is able to navigate through the dif-
ferent pages, most of which comprise data filters. Some of the menu
options contain dropdown submenus, which automatically display once
the user hovers the cursor over it. Apart from the menu, the header
component also includes the registration buttons, where new and ex-
isting users can sign up or sign in, respectively. For screens that are
smaller than 700 pixels, such as tablets and mobile phones, where the
menu bar would not be ideal for the user, it was replaced with a menu
button, also known as a hamburger icon (Figure 1b). By tapping on this
icon, the user is able to see the menu as a dropdown list (Figure 1b) and
by tapping each of the options he/she can navigate through the different
pages or unravel the submenus where applicable.
The main part between the header and the footer varies and
includes different data filters. Those filters are designed to facilitate
data querying and to expedite data output, the latter delivered in a
tabular format, which can be paginated for lengthy data outputs.
2.2 | Client side, react, and user interface
We used the ReactJS framework to implement the front‐end inter-
face. There are five different filters to help the user toward data
querying, which is implemented on a different page, described as
following.
1. Data querying using the World Map. In this filter, as shown in
Figure 2a, a world map is depicted where the user can zoom in
and out using the corresponding buttons on the right side. The
user is also able to slide the map to any directions just by dragging
it. The countries with green color are clickable, indicating that for
those populations, data are available, while no data are available
for countries shown in red. Once the user clicks on a country on
F IGURE 1 The new FINDbase user interface for desktops (a) and mobile devices (b). The various menu items are also graphically depicted.
The Login/Sign Up options are displayed at the top right part of the menu bar (see also text for details)
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the world map, ReactJS will fetch all available data in the data
warehouse for this population and will display them in the tables
below. In the top table, allele frequency data for pathogenic
variants leading to inherited diseases are provided, whereas the
bottom table shows allele frequency data for PGx biomarkers.
2. Data querying per Disease. This filter is a simple input with the
autocomplete feature for all the existing diseases in our database
(Figure 3a). Data output is in the form of a single table that will show
the allele frequencies of all variants leading to the selected genetic
disease in the available populations in the data warehouse.
F IGURE 2 Data querying interface using the Population Map option. The user can zoom in and out using the options available at the bottom
right corner of the map and can select a population from the countries in the world map, colored in green (see also text). In the case of this
particular query, the Romanian population is selected, a query that returns 23 records in a tabular format
F IGURE 3 Data querying interface using the Disease option. The user can select the Disease from the specified Disease list. In the case of
this particular query, query selection for Cystic Fibrosis, the output includes 1,769 records in a tabular format
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3. Data querying per Gene: In this filter, there are two autocomplete
fields, where the user can query for different variants in genes
leading to genetic diseases (left‐hand filter) or pharmacogenes
(right‐hand filter; Figure 4a). The output of this query is in the
form of a table that shows the allele frequencies of this gene
across all available populations. Notably, the table is a dynamic
element that changes its headers depending on whether a
disease‐associated gene or a pharmacogene is queried.
4. Data querying per Allele Frequency: This filter consists of two
parts, as shown in Figure 5a. In the top part, there is an auto-
complete input field, where the user selects the desired country,
for which data are available in the FINDbase data warehouse.
Subsequently, the user can define the frequency range of the
variant or allele of interest using a two‐sided slider between 0.00
and 0.50. Once the frequency range is selected, the data output is
given in a single table format.
5. Data querying per Researchers: FINDbase data contribution is
based on microattribution, which encourages data sharing in the
public domain (Giardine et al., 2011; Patrinos et al., 2012). Based
on this concept, this filter allows querying of the data contributed
to the database per contributor, based on his or her Re-
searcherID. Again, this filter is a single autocomplete input field,
similar to the one available for Diseases, and data querying is
based on the ResearchersID. For this filter, data output is pro-
vided in two different tables, one for pathogenic variants leading
to genetic diseases and another table for PGx biomarkers.
2.3 | Registration and data entry
The updated FINDbase uses a tiered structure for data entry and
modification.
1. Administrators: They have full access rights to all database con-
tents, functionalities, and menus. This category has rights for data
entry as well as modification, registration, and account activation
for the second category of registered users. This category is re-
sponsible for managing the overall development and maintenance
of FINDbase.
2. Registered users: This is the most important group in the next‐
generation FINDbase and refers to those users that tangibly con-
tribute to the database content and maintenance. As previously
mentioned, FINDbase is based on microattribution, which aims to
incentivize genomic data submission to the public domain (Giardine
et al., 2011). As such, registered users are individuals that have
deposited clinically relevant genomic variant allele frequency data
in FINDbase. These users have access to all data, that is, also to
those data that are not available to unregistered users. This kind of
role can be requested using the “Sign Up” button (Figure 6). The
request is then automatically sent to the administrator, who will
guide the user through the next steps to complete the registration
and contribute data to FINDbase. This user group is crucial for the
long‐term sustainability of the resource.
3. Plain (nonregistered) users: This user group can only access
publicly available FINDbase data.
3 | RESULTS
3.1 | Technical aspects, data querying, and database
architecture
The implementation of modern development tools is among the
major updates of the next‐generation FINDbase. The updated back‐end
approach utilizing Django as well as the implementation of the front‐end
utilizing ReactJS, provide a notably quicker response rate, that is in less
than a second. Concretely, ReactJS constitutes a synchronous, solid, and
fast framework being able to quickly connect to a server and simulta-
neously fetch responses for multiple different queries.
The representation of the back‐end unit is illustrated in the da-
tabase scheme of Figure 7. The main implementation tool for
FINDbase utilizes the Django REST framework and the used version
constitutes the newest Django approach, which provides server link
queries to receive the data. The implementation of search queries
relies on knowledge of the corresponding database structure to
connect the tables via join operations and finally to get the requested
information that the pages provide.
Another advantage of the abovementioned frameworks concerns
their widespread use among the majority of developers and specifi-
cally, which they can provide modern solutions for numerous dif-
ferent applications with the aim of improving and increasing these
systems' stability. Furthermore, this aspect ensures that none of
these frameworks will be deprecated in the next years and hence, the
proposed system will maintain its performance.
3.2 | Data content enrichment
Contrary to the previous FINDbase data content updates in 2010
(Georgitsi et al., 2011a; 2011b), 2013 (Papadopoulos et al., 2014) and
2016 (Viennas et al., 2017), the current content update did not only
include data curation, updates, and corrections, but also extensive
data enrichment. In particular, FINDbase data collection was
enriched mostly with PGx biomarker allele frequencies, derived
from two large genotyping efforts that evaluated the prevalence of
clinically actionable PGx biomarkers in more than 20, mostly
European, populations (see Mizzi et al., 2016; Patrinos et al., 2012;
Petrović, Pešić, & Lauschke, 2020). This data update is of relevance for
geneticists, drug developers, and clinicians, as it allows to assess the
prevalence of PGx biomarkers that can impact the efficacy or toxicity of
a given drug in the population of interest, thus guiding the prescription
of PGx testing to individualize drug treatment and assisting in finding
suitable countries for clinical trials of novel drug candidates.
As stated above, FINDbase data records include two different
modules, namely (a) pathogenic genomic variants and (b) PGx
biomarkers. Details of the data content in both data modules are
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F IGURE 4 Data querying interface using the Gene option. The user can select between genes involved in genetic disease and
pharmacogenes. In the case of the queries below, querying for G6PD (a), the query returns 16 records, while in the case of CYP3A5 (b), the
query returns 142 records, both in a tabular format. In the latter case of the pharmacogene, the variant's alternative nomenclature (as a * allele)
is also displayed at the last column in the table
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F IGURE 5 Data querying interface using the Allele Frequency option. The user first needs to select the Population (Iran in this particular
query) and then determine the allele frequency range (low‐ and high‐frequency value) using the two‐sided slider. In the case of this particular
query (variants in the Iranian population with an allele frequency range between 30% and 50%), the query output includes 10 records in a
tabular format., corresponding to the frequent variants documented for this population
F IGURE 6 Modules for signing up (a) and
logging in to FINDbase (b)
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summarized in Table 1. An important feature of the updated FIND-
base content is the split of the data content into a public section,
which are open to all users, as well as a private section, which can
only be accessed by registered users and administrators.
(a) The Public section includes 8,895 publicly available data entries of
which 6,035 correspond to pathogenic genomic variants distributed
across 25 genes and 2,860 correspond to PGx biomarkers in
18 genes (Figure 8 and Table 1).
(b) The Private section includes additional 21,578 data records,
which can be accessed by FINDbase users that have tangibly
contributed with data content. This section currently comprises
only of PGx biomarkers in 233 genes (Table 1).
FINDbase data compilation and representation are subject to
copyright and usage principles to ensure that FINDbase and its
contents remains freely available to all interested parties.
4 | DISCUSSION
Comprehensive documentation of the extant genetic ethnogeographic
heterogeneity across different populations is key for the accurate
provision of personalized medicine services. General databases such
as ClinVar (https://www.ncbi.nlm.nih.gov/clinvar) provide information
about genotype‐phenotype relationships but do not contain
population‐specific variant frequency data. In contrast, genomic da-
tabases, such as gnomAD (https://gnomad.broadinstitute.org) provide
important information regarding variant frequencies. However, these
data are not linked to phenotypic outcomes and frequency information
is highly aggregated and not available for individual countries. In the
past, several databases have tried to address this gap of providing
phenotypically annotated variant allele frequencies but with limited to
no success. One such resource is the Allele Frequency Net Database
(http://www.allelefrequencies.net/default.asp), which only documents
the allele frequencies of HLA alleles and other immune‐related genes;
as such its content is somewhat limited. Another resource is the Allele
Frequency Database (ALFRED; https://alfred.med.yale.edu/alfred/
index.asp), which has been designed to make allele frequency data
on anthropologically defined human population samples readily avail-
able to the scientific community and to link these polymorphism data
to the molecular genetics‐human genome databases. This resource,
however, does not provide allele frequency data for clinically relevant
genomic variants.
The concept of FINDbase is very different from other databases
that have attempted to address this task. FINDbase focuses ex-
clusively on clinically relevant and actionable variations for which
population‐specific frequency information is available and, as such,
covers a niche that is not systematically covered in other genomic
resources. Also, these data nicely complement with data of other
resources, such as the CFRT2 (www.cftr2.org) or the database of the
International Society of Gastrointestinal Hereditary Tumors (www.
insight‐group.org), which also take into account the penetrance of
pathogenic variants in a more comprehensive and structured manner,
compared with other LSDBs. The resulting utility for researchers and
clinicians is supported by the sustainability of this resource, its
F IGURE 7 Database schema of the next‐generation FINDbase
TABLE 1 Summary of the next‐generation FINDbase data content
Features
Public
records
Private
records
Total
records
Populations 174 33 207
Genes (diseases) 25 0 25
Pharmacogenes 18 233 251
Genes (total) 43 233 276
Causative genomic variants 6,035 0 6,035
Pharmacogenomic variants 2,860 21,578 24,438
Common variants (>10%) 1,905 5,221 7,126
Rare variants (<1%) 4,568 11,895 16,463
Records of genomic variants (total) 8,895 21,578 30,473
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continuous update and upgrade and uninterrupted funding since its
inception in 2006, one important feature of successful genomic
databases and resources (Patrinos & Brookes, 2005).
The recent FINDbase update was initiated in mid‐2018 and
covered different aspects, aiming (a) to significantly enrich the
existing data collection with PGx biomarker allele frequency data, (b) to
upgrade the entire database structure and querying engine to optimize
speed and efficiency of data output, (c) to refurbish the database front
end to improve the end user experience, and (d) to strengthen the
implementation of microattribution (Giardine et al., 2011; Patrinos
et al., 2012), by rewarding genomic data sharing with extended access
permissions. The latter is of utmost importance since it ensures the
long‐term viability and continuous update of the resource. Notably,
funding for the maintenance and upgrade of FINDbase is secured for
another 4‐year period from European projects and private sponsors,
which corroborates the value and impact of the database for the
scientific community, since opportunities for funding database projects
are difficult to secure (Patrinos & Brookes, 2005).
While data updates and enrichments are crucial for genomic
databases, we feel that both the redesign of the database querying
engine as well as linking genomic variant allelic frequency data sharing
with database access were the hallmarks of the next‐generation
FINDbase that would further strengthen its sustainability. In parti-
cular, the new database querying engine not only significantly expedited
the data output to milliseconds, compared with the lengthy waiting
times of the previous Pivot viewer‐based interface but also, and most
importantly, allowed the significant expansion of FINDbase data
collection to more than threefold, compared to the previous version.
The updated FINDbase design does not allow yet to display
autonomous NEGDBs per population, as implemented in the previous
update (Viennas et al., 2017), which are either hosted separately in
the FINDbase server or remotely but as part of the future design, this
F IGURE 8 Histogram depicting the number of the pathogenic variants (a) and of the pharmacogenomic biomarkers (b), deposited in the
public version of FINDbase, clustered per gene
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will be further implemented to allow independent management of
these NEGDBs locally by experts, which would then update the
central FINDbase content. The latter will be facilitated by the fact
that both the NEGDBs and the central FINDbase databases will be
operating under the same frame, which contributes toward NEGDB
data content uniformity (Patrinos, 2006). This design will also allow
local experts that will serve as NEGDB curators to maintain NEGDB‐
specific pages that will differ from NEGDB to NEGDB and include
population‐specific information, such as local human genetic socie-
ties, conferences of interest, and so forth, which may not necessarily
appear in FINDbase itself.
The numerous large‐scale genome projects, which are currently
being implemented in several countries worldwide create un-
precedent opportunities for expanding the FINDbase data collection.
To accommodate the wealth of these data, FINDbase architecture
will have to be further modernized and adapted not only to store but
also to dynamically analyze genomic data, derived from next‐
generation sequencing in a continuous manner. As such, algorithms
are needed that automatically calculate the allelic frequencies of
genomic variants in clinically actionable genes, leading, for example,
to monogenic diseases, physiological traits, and/or pharmacogenes,
while guaranteeing data anonymity. These NGS data will be again
contributed using the microattribution approach, flagged with a
certain tag (e.g., an “mA” tag), and deposited using a DOI, hence
providing credit to data contributors and curators, apart from their
access to the private FINDbase data collection. Furthermore, we plan
the implementation of additional forms of unambiguous contributor
identifications, such as ORCID identifiers (http://www.orcid.org), in
addition to the currently included ResearcherID. This increase in data
coverage should be accompanied by additional data visualization
tools and possibly crosstalk with existing resources, such as ClinVar
and gnomAD, which would increase value, particularly for the epi-
demiology of rare variants, which already constitute a significant
proportion in the existing FINDbase data collection (Figure 9) and
reveal a possible high prevalence of certain variants in specific po-
pulation isolates.
In summary, the major 2019 update of FINDbase improves ac-
cessibility, functionality, and user experience and optimizes database
efficiency and runtimes due to the implementation of a modern Ja-
vascript framework. Furthermore, the substantially extended content
ensures that the updated FINDbase constitutes a state‐of‐the‐art
genomic database that provides important information about the
prevalence of clinically relevant variants, which constitutes a cor-
nerstone for genomic medicine and precision public health.
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